PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Alfuzosin hydrochloride - Benign prostatic hyperplasia
PAD Profile : Alfuzosin hydrochloride - Benign prostatic hyperplasia
Keywords :
BPH, LUTS, urinary tract symptoms, urinary frequency, urinary incontinence
Brand Names Include :
Xatral
Traffic Light Status
Status 1 of 1.
Status :
Green (see narrative)
Important
Formulations :
- Modified release tablets
- Tablets
Important Information :
2nd or 3rd line.
Tamsulosin MR capsules or Doxazosin immediate release tablets are preferred
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Comments :
No comments returned.
Documents :
Guidelines
No guidelines returned.
Other Drugs
- Tadalafil
- Tamsulosin and dutasteride hydrochloride
- Tamsulosin hydrochloride
- Doxazosin
- Terazosin hydrochloride
- Indoramin
- Prazosin hydrochloride
- Sildenafil
- Avanafil
- Vardenafil
- Tamsulosin with solifenacin
Other Indications
Additional Documents
No additional documents returned.
Committee Recommendations
Date
Committee Name
Narrative
06 December 2017
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
Where an alpha blocker is indicated, the PCN recommend one of the following as a 1st-line treatment option
- Tamsulosin (modified release) – GREEN (NOTE - prescribe as generic capsules)
- Doxazosin (immediate release) – GREEN (NOTE - XL / modified release preparations are considered BLACK)
Alfuzosin is more costly and is therefore not recommended as a 1st-line option. (NOTE - prescribe generically).
Terazosin is reserved for patients with hepatic or renal failure since no dose adjustment is required in these patient groups
Associated BNF Codes
07. Obstetrics, Gynaecology and Urinary-Tract Disorders
07.04.01. Drugs for urinary retention